Holen Sie sich die Stockscreener-App
0.0934
449.41%
0.0764
Galera Therapeutics Inc Aktie (GRTX) Neueste Nachrichten
Malvern-based Galera Therapeutics to be acquired in reverse merger - MSN
Emerald backs Galera–Obsidian deal with 26.5% Galera (GRTX) stake - Stock Titan
Galera, Obsidian Agree to Merge, Raise $350 Million in Financing - MyChesCo
Obsidian CEO Madan Jagasia Leads Merger with Galera Therapeutics Backed by $350M Financing - INDIA New England News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger-LEG, AVNS, GRTX, and GSAT - The Malaysian Reserve
Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Merger Deal: Galera Therapeutics (GRTX) to Merge with Obsidian; ASCO Phase 2 Data Ahead - Stock Titan
Galera Therapeutics (NASDAQ: GRTX) to merge with Obsidian; S-4 and proxy planned - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--LEG, AVNS, GRTX, and GSAT - Sahm
Galera, Obsidian to Merge, Raise $350 Million in Financing - MyChesCo
Are FORA, GRTX, WBS, TALK Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
[DEF 14A] Galera Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
United StatesGoodwin Advises Obsidian Therapeutics On Merger With Galera Therapeutics And $350 Million Private Placement Financing - Mondaq
Galera Therapeutics to merge with Obsidian in $350M deal By Investing.com - Investing.com Australia
Obsidian and Galera reveal reverse merger plan - The Pharma Letter
Obsidian, Galera to advance cell therapy following reverse merger - BioPharma Dive
Galera (GRTX) to Merge with Obsidian; $350M Financing Backs OBX‑115 - Stock Titan
M&A Class Action Firm Investigating Galera Acquisition - National Today
Galera and Obsidian Announce $350M Merger, Advancing Novel TIL Therapies - National Today
Merger: Galera to combine with Obsidian (NASDAQ: GRTX) with $350M PIPE commitment - Stock Titan
Obsidian Therapeutics (NASDAQ: OBX) to list after merger with Galera, $350M PIPE - Stock Titan
Galera Therapeutics (GRTX) to file Form S-4 for proposed Obsidian merger - Stock Titan
Galera Therapeutics (GRTX) to Merge with Obsidian Therapeutics - GuruFocus
Obsidian Therapeutics, Inc. agreed to acquire Galera Therapeutics, Inc. in a reverse merger transaction. - marketscreener.com
Galera Therapeutics to merge with Obsidian in $350M deal - Investing.com
Galera Therapeutics, Obsidian Therapeutics Announce Merger and $350M Private Placement - citybiz
GRTX | GALERA THERAPEUTICS INC Insider Trading - Quiver Quantitative
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Bluefield Daily Telegraph
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - ChartMill
Cell therapy biotech Obsidian leverages Galera reverse merger to go public - Fierce Biotech
Galera Therapeutics, Obsidian Therapeutics enter merger agreement - TipRanks
Galera Announces Obsidian Merger and $350M Financing - TipRanks
Galera Therapeutics (GRTX) to combine with Obsidian after $350M PIPE financing - Stock Titan
Galera Therapeutics to Merge With Obsidian; Secures $350 Million PIPE and Sets CVR for Legacy Assets - TradingView
Obsidian–Galera (OTC: GRTX) merger adds $350M PIPE to fund OBX-115 - Stock Titan
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - Weekly Voice
GALERA THERAPEUTICS INCCO AND OBSIDIAN TO MERGE IN ALL-STOCK DEAL - Moomoo
[PRE 14A] Galera Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Nancy T. Chang Discloses Investment at Galera Therapeutics with 5.9% Stake - TradingView
Director grows Galera (NASDAQ: GRTX) stake via private placement and merger - Stock Titan
Galera Therapeutics, Inc. Files Form 8-K: Company Information, Stock Symbol GRTX, and No Exchange Listing as of April 2026 - Minichart
Galera Therapeutics Announces Share Conversions and Warrant Exercise - TipRanks
Galera Therapeutics (GRTX) director IRA converts 5.34M preferred-linked shares - Stock Titan
[Form 4] Galera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Preferred conversion and warrant exercise reshape Galera (GRTX) common stock - Stock Titan
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary - Business Wire
Galera Sets Deadlines for 2026 Combined Annual Meeting - The Globe and Mail
Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia
Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView
Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan
Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView
2.23%
Kapitalisierung:
|
Volumen (24h):